Page 4 - Polyphor Ltd News Today

EQS-Adhoc: Polyphor AG: Polyphor to present full-year 2020 financial results on March 5 Polyphor to present full-year 2020 financial results on March 5 26-Feb-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, February 26, 2021 Polyphor to Present Full-Year 2020 Financial Results on March 5 Polyphor AG (SIX: POLN) announced today that it will publish its full-year financi...

Share this article Share this article ResearchAndMarkets.coms offering. Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts.The publisher has looked at the technology picture too, giving you, plain language understanding of the different wa...

News Category Global Banking & Finance Reviews Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event ALLSCHWIL, Switzerland, Jan. 05, 2021 — Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeS...

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin December 22, 2020 01:30 ET | Source: Polyphor AG Polyphor AG Allschwil, SWITZERLAND Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Polyp...

(2) EQS Group-Ad-hoc: Polyphor AG / Key word(s): Study Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications 14-Dec-2020 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, December 14, 2020 Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing ... Polyphor AGDecember 11, 2020 GMT ALLSCHWIL, Switzerland, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announced the extension of its existing grant agreement with CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global partnership led by Boston University dedicat...